国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2009年
13期
90-92
,共3页
拉米夫定%P-转移因子%慢性乙型肝炎
拉米伕定%P-轉移因子%慢性乙型肝炎
랍미부정%P-전이인자%만성을형간염
P-transfer factor lamivudine%hepatitis B%chronic
目的 探讨慢性乙型肝炎病毒(HBV)携带者的治疗方法 .方法 应用拉米夫定(Lamivudine)联合P-转移因子口服液治疗HBV携带者HBeAg、抗HBc-lgM、HBV DNA均阳性者75例为观察组,对照组38例只服拉米夫定,观察6～12个月.结果 治疗6个月时观察组HBeAg、抗-HBe、HBV DNA阴转达47.9%、15.4%和78.9%;对照组为28.8%、13.8%和68.1%;治疗12个月时,观察组HBeAg、抗-HBe、HBV DNA阴转达64.8%、36.7%和82.3%;对照组为36.6%、13.8%和68.2%.两组比较,差异有显著性(P＜0.05).结论 P-转移因子口服液能够提高HBV携带者对拉米夫定的生化学、血清学应答率,二者联合是一种较好的抗HBV的治疗方法 .
目的 探討慢性乙型肝炎病毒(HBV)攜帶者的治療方法 .方法 應用拉米伕定(Lamivudine)聯閤P-轉移因子口服液治療HBV攜帶者HBeAg、抗HBc-lgM、HBV DNA均暘性者75例為觀察組,對照組38例隻服拉米伕定,觀察6～12箇月.結果 治療6箇月時觀察組HBeAg、抗-HBe、HBV DNA陰轉達47.9%、15.4%和78.9%;對照組為28.8%、13.8%和68.1%;治療12箇月時,觀察組HBeAg、抗-HBe、HBV DNA陰轉達64.8%、36.7%和82.3%;對照組為36.6%、13.8%和68.2%.兩組比較,差異有顯著性(P＜0.05).結論 P-轉移因子口服液能夠提高HBV攜帶者對拉米伕定的生化學、血清學應答率,二者聯閤是一種較好的抗HBV的治療方法 .
목적 탐토만성을형간염병독(HBV)휴대자적치료방법 .방법 응용랍미부정(Lamivudine)연합P-전이인자구복액치료HBV휴대자HBeAg、항HBc-lgM、HBV DNA균양성자75례위관찰조,대조조38례지복랍미부정,관찰6～12개월.결과 치료6개월시관찰조HBeAg、항-HBe、HBV DNA음전체47.9%、15.4%화78.9%;대조조위28.8%、13.8%화68.1%;치료12개월시,관찰조HBeAg、항-HBe、HBV DNA음전체64.8%、36.7%화82.3%;대조조위36.6%、13.8%화68.2%.량조비교,차이유현저성(P＜0.05).결론 P-전이인자구복액능구제고HBV휴대자대랍미부정적생화학、혈청학응답솔,이자연합시일충교호적항HBV적치료방법 .
Objective To investigate the treatment ways of the chronic hepatitis B virus(HBV)carriers.Methods To drink oral solution of Lamivudine Joint P-transfer factor treatment for HBV carriers HBeAg,anti-HBc-IgM,HBVDNA were 75 cases positive for the observation group,38 cases were control group,only lamivudine service and observed for6-12 months.Results The treatment of 6 months observation group HBeAg,anti-HBe,HBVDNA conversion of 47.9%,15.4% and 78.9%;control group was 28.8%,13.8% and 68.1%;the treatment of 12 months,the Observer Group of HBeAg,antiHBe,HBVDN A conversion of 64.8%,36.7% and 82.3%;control group was 36.6%,13.8% and 68.2%.Comparing the two groups,there was a significant difference(P＜0.Q5).Conclusions Oral solution of P-transfer factor can improve the carriers of HBV lamivudine biochemistry,serological response rate,the two joint is a better anti-HBV treatment.
